









Supplemental Fig 1 (related to Fig 2A). Cytokine profiling of conditioned media from PEO1 and PEO4 cells. PEO1 and PEO4 cells were treated with IFN γ , static, or both in combination for 24 hr. Conditioned media were collected to determine the levels of 36 cytokines using a cytokine immunoarray. Chemiluminescent signals generated at individual capture spots were imaged. Each cytokine was detected at two duplicate spots. Representative cytokines are indicated with arrows. MIF is used as a loading control.




Supplemental Fig 2 (related to Fig 2C). Cytokine profiling of conditioned media from PEO1 and PEO4 cells. PEO1 and PEO4 cells were grown for 24 hr. Conditioned media were collected to determine the levels of 105 cytokines using a cytokine immunoarray. Chemiluminescent signals generated at individual capture spots were imaged. Each cytokine was detected at two duplicate spots. Cytokines that were up-regulated in PEO4 cells compared to PEO1 cells are indicated (Fig 2C). MIF is used as a loading control.



Supplemental Fig 3. Effects of PEO1 and PEO4 cells on SUPT1 cells. SUPT1 cells activated by CD3/CD28 antibodies were co-cultured with PEO1 or PEO4 cells for 48 hr. SUPT1 cells were collected, stained, and analyzed by a flow cytometer to determine the percentage of the FOXP3+CD4+CD25+ T cell population.


A**B**

Supplemental Fig 4. Effects of AMG487 or TAK779 in combination with bevacizumab (Bev) on peritoneal growth of p53(-/-) ID8 EOC in C57BL6 mice. Mice (n=3) were inoculated ip with ID8 cells and treated ip with vehicle, bevacizumab (Bev, 2 mg/kg, biw), AMG487 (5 mg/kg, tiw), and Bev plus AMG487 (A) or TAK779 (5 mg/kg, tiw) and Bev plus TAK779 (B) for 5 weeks. The ACs of mice were measured to determine the percentage increase in AC. *, $p < 0.05$.




	Median Survival Time (Day)
Control	41
Bev 5 mg/kg	43
AMG487 5 mg/kg	42
Bev+AMG487	48


Supplemental Fig 5 (related to Fig 7D). Effects of AMG487 and Bev combination on the survival of C57BL6 mice implanted with p53(-/-) ID8 EOC. Mice (n=5) were inoculated ip with ID8 cells and treated ip with vehicle, bevacizumab (Bev, 2 mg/kg, biw), AMG487 (5 mg/kg, tiw), and Bev plus AMG487 for 5 weeks. The Kaplan-Meier survival curve and median survival time of mice were determined using BCS2 as the endpoint.




Supplemental Fig 6 (related to Fig 1A). Full length gel images of PD-L1, γ H2AX, and HSC70 proteins.



Supplemental Fig 7 (related to Fig 1D). Full length gel images of PD-L1 and HSC70 protein.



Supplemental Fig 8 (related to Fig 5D). Full length gel images of CD73 and HSC70 proteins.



Supplemental Fig 9 (related to Fig 7E). Flow cytometry analysis of activated CD8+ and FOXP3+CD4+ T cells in mouse ascites. CD3+ T cells were isolated from ascites and stained with antibodies. CD3+ T cells were first gated for the FSC-A high sub-population and subsequently gated for CD8+ or FOXP3+CD4+ cells. The difference in the percentage between stained cells and non-stained cells was multiplied by the percentage of activated CD3+ T cells to obtain the percentage of activated CD8+ or activated FOXP3+CD4+ T cells in total CD3+ T cells. A representative mouse ascites from each treatment group is shown.